AVITA Medical, Inc.
AVITA Medical, Inc. (RCEL) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
rcel · stock forecast · 7 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 7 Wall Street analysts in the past 3 months
Buy
7 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$10.00
Consensus
$8.00
+92.3% upside
Low
$6.00
Median: $8 · Last Close: $4.16
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$8.00
92.3% upside
High Target
$10
140.4%
Low Target
$6
44.2%
Current Price
$4.16
as of today
Based on analyst price targets, the RCEL stock price prediction for the next 12 months ranges from $6 to $10. The consensus RCEL price forecast of $8.00 implies 92.3% upside from the current price of $4.16.
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $4.09 | ↓ 1.69% |
1-day model range: $4.06–$4.12. Peak: $4.12 (-1.69%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · RCEL · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-15 | Lake Street | Upgrade ↑ | Hold→Buy |
| 2026-04-09 | D. Boral Capital | Maintains | Buy→Buy |
| 2026-04-08 | D. Boral Capital | Maintains | Buy→Buy |
| 2026-02-17 | D. Boral Capital | Maintains | Buy→Buy |
| 2026-01-26 | D. Boral Capital | Maintains | Buy→Buy |
| 2026-01-16 | Lake Street | Maintains | Hold→Hold |
| 2026-01-15 | D. Boral Capital | Maintains | Buy→Buy |
| 2025-11-20 | BTIG | Upgrade ↑ | Sell→Neutral |
| 2025-11-07 | D. Boral Capital | Maintains | Buy→Buy |
| 2025-10-17 | D. Boral Capital | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on AVITA Medical, Inc. (RCEL) stock. Of the recent 54 rating actions, 2 were upgrades and 3 were downgrades. 7 analysts currently cover RCEL.
Analyst Recommendation Trends
RCEL analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$82M
↓ 32.9% YoY
Revenue Next Year
$100M
↑ 21.0% YoY
EPS This Year
$-1.10
EPS Next Year
$-0.69
↓ 37.6% YoY
EPS ForecastReported vs Estimated
Analysts forecast RCEL EPS of $-1.10 for the current fiscal year, based on estimates from 4 analysts. The RCEL revenue forecast is $82M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The RCEL stock forecast is supported by two independent data sources: analyst consensus ratings from 7 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus RCEL price target is $8.00 (+92.3% upside), with an analyst consensus of Buy.
The RCEL short-term stock prediction for tomorrow is $4.09 (-1.69%).
AVITA Medical, Inc. trades on NASDAQ under the ticker RCEL. The RCEL stock outlook for 2027 is broadly positive, supported by a Buy consensus among 71% of covering analysts.
Frequently asked questions
RCEL forecast · 8 questionsAccording to 7 Wall Street analysts, the average 12-month RCEL price target is $8.00, with a high forecast of $10.00 and a low of $6.00. The median price target is shown in the chart above when available. This implies +92.3% potential upside from the current price of $4.16.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.